Azenta Life Sciences’ Post

September is National Sickle Cell Awareness Month, a critical time to highlight the challenges faced by over 100,000 Americans living with sickle cell disease (SCD). Patients with SCD often require complex therapies, frequent hospitalizations and specialized medication management to prevent complications like organ damage. Learn more about our partner Children's National Hospital who treated the first patient with new sickle cell gene therapy. 🔗https://ow.ly/mgoE50TgLqf #SickleCellAwareness #SpecialtyPharmacy #ClearwayHealth #PatientOutcomes #MedicationManagement Source: https://ow.ly/B3XE50TgLqg

🌍✨ Cell and gene therapies (CGTx) hold incredible promise for treating Cancer and rare genetic diseases, but global access and operational challenges still stand in the way. By expanding trial sites, embracing patient-centric technology, and prioritizing patient diversity, we can accelerate advancements and make transformative treatments accessible to all. Read the opinion of our Founder & CEO, Harsha K Rajasimha, Ph.D. from this Healthcare Business Today's Article: https://hubs.la/Q02M9SRs0 #clinicalresearch #genetherapy #clinicaltrials #medicalresearch #cellandgenetherapy

Discover the remarkable advancements in #globalhealthcare, driving improvements in health outcomes and saving millions of lives. 🚀 Things you will learn in this article: 1. How vaccines have revolutionized #preventativecare and saved millions of lives 2. #Innovativetreatments like targeted therapies, immunotherapies, and gene therapies transforming cancer treatment and genetic disorder management 3. #Telemedicine and #digitalhealth technologies expanding access and improving patient outcomes 4. Advances in #personalizedmedicine and #CRISPR gene editing offer new hope for previously untreatable conditions 5. #Regenerativemedicine's potential to repair and replace damaged tissues and organs Dive deeper into the article - https://bit.ly/4cFVMGA

September is Inherited Retinal Disease Awareness Month. There are currently 2 million+ people worldwide who are at risk of losing their eyesight due to an inherited retinal disease, and we’re aiming to raise awareness and bring hope to those who may be suffering. Kiora Pharmaceuticals’ KIO-301 is an innovative drug aiming to restore functional vision by making retinal ganglion cells light sensitive. KIO-301 is not a gene therapy, but a small molecule potentially capable of restoring lost vision in patients with inherited retinal diseases. Learn more about KIO-301 here: https://lnkd.in/eA9HQ6My #kiorapharmaceuticals #visionrestoration #retinaldiseases #innovativemedicine #sightloss #InheritedRetinalDiseaseAwarenessMonth

For decades, treatment options for sickle cell disease have been limited to blood transfusions, pain management, and medications like hydroxyurea, which can reduce the frequency of sickle cell crises. However, these treatments only address symptoms and do not target the underlying genetic cause of the disease. Enter gene therapy, a groundbreaking approach that offers the potential to cure sickle cell disease by correcting the faulty gene responsible for the condition. Read more here: https://lnkd.in/eW7gKTUw

As we approach Rare Disease Awareness Day, Odylia honors our Brydge Solutions partnership with The Usher 2020 Foundation (Susie Trotochaud) and the FAUN Foundation. Through this partnership and the group of collaborators we have brought together we are developing a gene therapy to treat vision loss in patients with Usher Syndrome Type 1 caused by mutations in the USH1C gene. Patients have profound hearing loss usually from birth, vestibular dysfunction, and vision loss beginning in early adolescence. We are honored to work with these incredible foundations towards their goal of treating vision loss in USH1C patients. #rarediseaseawareness #raredisease #visionloss #genetherapy #drugdevelopment #rarediseaseawareness2024 #leapday #brydgesolutions #USH1C #UsherSyndrome

In this eBook, "What’s Next: Future Trends in Immune Cell Therapy", explore groundbreaking strategies and the latest trends shaping the future of cell and gene therapies. #eBook #ImmuneCellTherapy #CellTherapies #GeneTherapies #Agilent https://lnkd.in/gCh29Y96 Explore next generation solutions for cell therapies https://lnkd.in/gvQXaY-H

Thrilled to announce that our poster has been accepted for presentation at the AMCP 2024 conference in New Orleans! In today's dynamic healthcare landscape, cell and gene therapies are revolutionizing disease treatment, with new therapies expected to hit the market at an unprecedented rate. Our research focuses on understanding the impact of route of administration on access and reimbursement of cell and gene therapies from the perspective of US payers. If you're attending AMCP 2024, stop by for a brief discussion on the future of cell and gene therapies. I'm eager to exchange perspectives and insights on the evolving landscape of access and reimbursement for those novel treatments. Let's connect and explore this topic at AMCP! #AMCP2024 #CellAndGeneTherapies #HealthcareInnovation #MarketAccess

We are honored to share that Andelyn has been selected by Armatus Bio, Inc. to accelerate manufacturing of their gene therapy treatment for Charcot-Marie-Tooth Type 1A (CMT1A), a rare genetic neurological disease associated with independence-limiting disability and risk of fatal complications that has no approved therapies today.   Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. People with this disease experience weakness and wasting (atrophy) of the muscles of the lower legs beginning in adolescence; later they can also have hand weakness and sensory loss. CMT1A is caused by having an extra copy (a duplication) of the PMP22 gene (NIH).   We are truly grateful to play an important role in directly transforming patient lives. https://lnkd.in/e3WBkyYU   #GeneTherapy #RareDisease #CDMO #aav

Cell and gene therapies (CGTs) have the potential to transform medicine across a spectrum of disease areas. However, the clinical trials landscape for these cutting-edge therapies is intricate, encompassing numerous touchpoints, diverse providers and locations, and considerable expenses, all of which can negatively affect the patient journey. A collaborative, concerted effort in development and manufacturing strategies — as well as a patient-centric approach to trial design — through an integrated #CRO and #CDMO partnership can streamline these intricacies and prioritize the patient experience. Find out how » https://bit.ly/4cUubST #cellandgenetherapy #CGT #clinicaltrials